A REVIEW ON COMPARISON OF DIFFERENT TECHNIQUES USED TO ENHANCE DISSOLUTION OF VALSARTAN AND TELMISARTAN ORAL SOLID DOSAGE FORM

20-HJPV4(1)-2022 Review Article

Abstract

Telmisartan and Valsartan are strong angiotensin-II type 1 receptor inhibitor, applied in the care of elevated blood pressure. Telmisartan and also Valsartan comes under Class II category of BCS classification. Valsartan and Telmisartan both are highly pH dependent and poor soluble drug which result in improper absorption and low bioavailability (43% and 23% respectively). In order to control the poor solubility as well as bioavailability of both Telmisartan and Valsartan, different formulation techniques are compared on the basis of dissolution. In this review article, solid dispersion by kneading method, pelletization by pan coating, modified microcrystalline cellulose (MCC) pellets and solid self-micro-emulsifying drug delivery system (SMEDDS) formulation techniques are discussed for Telmisartan. Whereas, in case of Valsartan, liquisolid compact technique, fast disintegrating tablets (FDT), and formulation optimized by 23 factorial designs are evaluated. To sum up, the analogy of Telmisartan formulations demonstrates that solid dispersion (TS5) and fast dissolving pellet formulation (TP3), both the techniques showed better drug release profile than MCC pellet and SMEDDS techniques. However, when it comes to dissolution rate, fast dissolving pellet formulation reflects notably best results among all. Furthermore, Valsartan formulation techniques evaluation leads us to conclude that liquisolid method showed good release profile as compare to conventional products but the method incorporates some complex requirements of load factor calculation and saturation solubility studies. In addition to that, Valsartan formulation optimized by factorial design as well as fast dissolving tablet (FDT) formulation signifies more conventional approach as well as good drug release profile.